Galecto Biotech
PublicGalecto Biotech is now publicly traded
The data on this page reflects Galecto Biotech's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Oct 28, 2020
Last Round
Follow-on Offering
Feb 12, 2026
Total Funding Raised
$844.2M
Company Overview
Damora Therapeutics, Inc. is a clinical-stage biotechnology company that develops biologics for the treatment of mutant calreticulin-driven myeloproliferative neoplasms.
Sector
Healthcare
AI Layer
Non-AI
Keywords
Galecto Biotech Comparables
Compare Galecto Biotech with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Eli Lilly and Company | 79% | |
| Galectin Therapeutics Inc | 79% | |
| Merck & Co., Inc. | 78% |
For institutional investors. Book with your work email.
Galecto Biotech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Feb 12, 2026 | ||||
| Private Placement | Nov 10, 2025 | ||||
| IPO | Oct 28, 2020 | ||||
| Series D | Sep 25, 2020 | ||||
| Series C | Oct 26, 2018 | ||||
Series A | Oct 30, 2013 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Galecto Biotech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Private Placement |
| Heartcore Capital | Series A, Seed, Series C, Series D |
| Jefferies | Follow-on Offering |
| Soleus Capital | Series D |
| Janus Henderson Group | Series D, Private Placement |
| Balyasny Asset Management L.P. | Private Placement |
| RA Capital Management | Private Placement |
For institutional investors. Book with your work email.
Galecto Biotech Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.